Journey Medical (US:DERM) Globenewswire·2025-10-24 12:30Core Insights - Journey Medical Corporation presented efficacy data for DFD-29 (Emrosi) at the 2025 Fall Clinical Dermatology Conference, demonstrating its superiority over both placebo and Oracea in treating inflammatory lesions of rosacea [1][2][3] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions, currently marketing eight branded drugs [11] Clinical Trial Results - In the Phase 3 trials, 62.7% of subjects treated with DFD-29 achieved IGA treatment success, compared to 39.0% for Oracea and 28.2% for placebo, with all comparisons showing statistical significance (p<0.001) [3][4][6] - The mean reduction in inflammatory lesions for DFD-29 was 19.2, compared to 14.8 for Oracea and 11.3 for placebo, also statistically significant (p<0.001) [3][4][6] Market Position - The results from the Phase 3 trials reinforce Emrosi's efficacy and safety profile, positioning it as a significant treatment option in the growing dermatology market [2][6] - The company aims to expand Emrosi's reach, believing it has the potential to become the standard of care for rosacea [2]